Ipratropio Bromuro/Salbutamol Cipla (Salbutamol, Ipratropium Bromide Monohydrate)

Ipratropium bromide blocks muscarinic receptors, preventing acetylcholine‑induced bronchoconstriction, while salbutamol stimulates β2‑adrenergic receptors, increasing cyclic AMP and relaxing airway smooth muscle. Together they produce a synergistic bronchodilatory effect that opens the airways more effectively than either agent alone.

The prescribed dose of Ipratropio Bromuro/Salbutamol Cipla is determined by the treating physician based on the patient’s clinical condition, severity of bronchospasm, and response to therapy. Dosage instructions are provided on the prescription label and should be followed exactly as directed.

Safety data for ipratropium bromide and salbutamol during pregnancy and lactation are limited. The product should only be used if the potential benefit justifies any potential risk to the fetus or infant. Healthcare providers should evaluate each case individually and discuss possible risks with the patient.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Compared with single‑agent inhalers, the ipratropium/salbutamol combination offers dual mechanisms—anticholinergic and β2‑agonist—providing broader bronchodilation. This can result in faster symptom relief and improved lung function, especially in patients who do not respond adequately to monotherapy.

Store the inhalation product at ambient temperature, preferably below 25 °C. Keep it in the original packaging, protect it from moisture and direct sunlight, and ensure the canister is tightly closed when not in use to maintain drug stability.

The medication is delivered via a metered‑dose inhaler or nebulizer, depending on the formulation supplied. The patient inhales the prescribed number of puffs or nebulized doses as instructed by the prescriber, typically using a spacer or face mask for optimal drug deposition in the lungs.

Serious adverse events include paradoxical bronchospasm, severe tachycardia or arrhythmia, significant hypokalemia, and rare allergic reactions such as anaphylaxis. Patients should seek immediate medical attention if they experience sudden worsening of breathing, chest pain, rapid heartbeat, or signs of an allergic response.

Individuals with a known hypersensitivity to ipratropium bromide, salbutamol, or any excipients in the formulation should avoid this product. It is also contraindicated in patients with severe narrow‑angle glaucoma and should be used with caution in those with significant cardiovascular disease.